Financial reports
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Unregistered Sales of Equity Securities
22 Mar 24
8-K
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
8-K
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14 Feb 24
8-K
Other Events
11 Dec 23
8-K
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
2 Nov 23
8-K
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8 Aug 23
8-K
Entry into a Material Definitive Agreement
8 Jun 23
8-K
Departure of Directors or Certain Officers
7 Jun 23
8-K
Other Events
6 Jun 23
8-K
Cogent Biosciences Reports Recent Business Highlights and First Quarter
9 May 23
Registration and prospectus
S-3
Shelf registration
29 Mar 24
S-8
Registration of securities for employees
26 Feb 24
S-8
Registration of securities for employees
8 Aug 23
424B5
Prospectus supplement for primary offering
8 Jun 23
424B5
Prospectus supplement for primary offering
6 Jun 23
S-8
Registration of securities for employees
14 Mar 23
S-3ASR
Automatic shelf registration
10 Feb 23
424B5
Prospectus supplement for primary offering
15 Jun 22
FWP
Free writing prospectus
13 Jun 22
424B5
Prospectus supplement for primary offering
13 Jun 22
Proxies
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEFM14A
Proxy related to merger
9 Oct 20
Other
EFFECT
Notice of effectiveness
11 Apr 24
EFFECT
Notice of effectiveness
25 May 22
CORRESP
Correspondence with SEC
20 May 22
UPLOAD
Letter from SEC
17 May 22
EFFECT
Notice of effectiveness
13 May 22
SEC STAFF
SEC staff action: Order
31 Mar 21
EFFECT
Notice of effectiveness
19 Mar 21
CORRESP
Correspondence with SEC
16 Mar 21
SEC STAFF
SEC staff action: Order
3 Mar 21
UPLOAD
Letter from SEC
12 Feb 21
Ownership
4
Karen Jean Ferrante
2 Apr 24
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
4
Change in insider ownership
1 Apr 24
SC 13D/A
Fairmount Funds Management LLC
27 Mar 24
SC 13D/A
Fairmount Funds Management LLC
16 Feb 24
4
Change in insider ownership
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24